Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282397 · ClinicalTrials.gov registry record · NA
Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes
A NA study, sponsored by DexCom.
- Completed
- Registry status
- NA
- Development phase
- 316
- Enrollment target
NCT02282397 is a NA study that has completed, run by DexCom. The registered enrollment target is 316 participants.
The verdict
NCT02282397, a NA study, has completed, sponsored by DexCom.
- COMPLETED
- Registry status
- NA
- Development phase
- 316 participants
- Enrollment target
Study Summary
Evaluate if addition and use of real time continuous glucose monitoring (RT-CGM) improves glycemic outcome of patients using multiple daily injections (MDI) and self monitoring blood glucose (SMBG) testing, who are not at target glycemic control.
Interventions
- DEVICE Continuous Glucose Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282397
The ClinicalTrials.gov registry entry for NCT02282397 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DexCom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Continuous Glucose Monitor is the first listed.
NCT02282397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02282397 about?
NCT02282397 is a clinical study titled "Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes". Evaluate if addition and use of real time continuous glucose monitoring (RT-CGM) improves glycemic outcome of patients using multiple daily injections (MDI) and self monitoring blood glucose (SMBG) testing, who are not at target glycemic control.
What is the current status of trial NCT02282397?
This trial is currently completed. It is a NA study. The enrollment target is 316 participants. The study started on 2014-09. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02282397?
The interventions under investigation include: Continuous Glucose Monitor (DEVICE).
Who is sponsoring clinical trial NCT02282397?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.